Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

被引：20
|
作者：
Delabaudiere, Cyrielle [1 ]
Lavayssiere, Laurence [1 ]
Doerr, Gaelle [1 ]
Muscari, Fabrice [2 ,3 ]
Danjoux, Marie [4 ]
Sallusto, Federico [5 ]
Peron, Jean Marie [3 ,6 ]
Bureau, Christophe [3 ,6 ]
Rostaing, Lionel [1 ,3 ,7 ]
Izopet, Jacques [3 ,7 ,8 ]
Kamar, Nassim [1 ,3 ,7 ]
机构：
[1] CHU Rangueil, Dept Nephrol & Organ Transplantat, F-31059 Toulouse 9, France
[2] Univ Hosp Rangueil, Dept Surg & Liver Transplantat, Toulouse, France
[3] Univ Toulouse 3, F-31062 Toulouse, France
[4] CHU Purpan, Dept Pathol, Toulouse, France
[5] CHU Rangueil, Dept Urol & Kidney Transplantat, F-31059 Toulouse 9, France
[6] CHU Purpan, Dept Hepatol, Federat Digest, Toulouse, France
[7] CHU Purpan, IFR BMT, INSERM, U1043, Toulouse, France
[8] CHU Purpan, Virol Lab, Toulouse, France
来源：
TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 02期
关键词：
fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir; RECIPIENTS; THERAPY; PEGINTERFERON; INFECTION; ALPHA;
D O I：
10.1111/tri.12428
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.
引用
收藏
页码：255 / 258
页数：4
相关论文
共 50 条
  • [1] Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
    Kim, Brian
    Trivedi, Anshu
    Thung, Swan N.
    Grewal, Priya
    SEMINARS IN LIVER DISEASE, 2014, 34 (01) : 108 - 112
  • [2] Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
    Issa, D.
    Eghtesad, B.
    Zein, N. N.
    Yerian, L.
    Cruise, M.
    Alkhouri, N.
    Adams, R.
    Hanouneh, I. A.
    INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 2016, 7 (01): : 38 - 45
  • [3] Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient
    Borentain, Patrick
    Colson, Philippe
    Dhiver, Catherine
    Gregoire, Emilie
    Hardwigsen, Jean
    Botta-Fridlund, Danielle
    Garcia, Stephane
    Gerolami, Rene
    ANTIVIRAL THERAPY, 2015, 20 (03) : 353 - 356
  • [4] Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report
    Jung, B. -H.
    Park, J. -I.
    Lee, S. -G.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (09) : 2877 - 2881
  • [5] An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
    Nikroo Hashemi
    Victor Araya
    Kashif Tufail
    Laxmi Thummalakunta
    Eyob Feyssa
    Ashaur Azhar
    Mumtaz Niazi
    Jorge Ortiz
    World Journal of Hepatology, 2011, 3 (07) : 198 - 204
  • [6] An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
    Hashemi, Nikroo
    Araya, Victor
    Tufail, Kashif
    Thummalakunta, Laxmi
    Feyssa, Eyob
    Azhar, Ashaur
    Niazi, Mumtaz
    Ortiz, Jorge
    WORLD JOURNAL OF HEPATOLOGY, 2011, 3 (07) : 198 - 204
  • [7] Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation
    Leroy, Vincent
    Dumortier, Jerome
    Coilly, Audrey
    Sebagh, Mylene
    Fougerou-Leurent, Claire
    Radenne, Sylvie
    Botta, Danielle
    Durand, Francois
    Silvain, Christine
    Lebray, Pascal
    Houssel-Debry, Pauline
    Kamar, Nassim
    D'Alteroche, Louis
    Petrov-Sanchez, Ventzislava
    Diallo, Alpha
    Pageaux, Georges-Philippe
    Duclos-Vallee, Jean-Charles
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) : 1993 - +
  • [8] Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation
    Dinges, S.
    Morard, I.
    Heim, M.
    Dufour, J.-F.
    Mullhaupt, B.
    Giostra, E.
    Clavien, P. -A.
    Mentha, G.
    Negro, F.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 33 - 39
  • [9] Unique pattern of fibrosing cholestatic hepatitis after liver transplantation
    Jia-Wei Chen
    Da-Zhi Chen
    Zhao-Min Chen From the Departments of Pathology and Surgery
    Hepatobiliary&PancreaticDiseasesInternational, 2002, (01) : 33 - 34
  • [10] Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin
    Tang, S
    Cheng, IKP
    Leung, VKS
    Kuok, UI
    Tang, AWC
    Ho, YW
    Lai, KN
    Chan, TM
    JOURNAL OF HEPATOLOGY, 2003, 39 (05) : 875 - 878
12345